GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mainz Biomed NV (NAS:MYNZ) » Definitions » Gross Margin %

MYNZ (Mainz Biomed NV) Gross Margin % : 0.00% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Mainz Biomed NV Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Mainz Biomed NV's Gross Profit for the three months ended in Dec. 2024 was $0.00 Mil. Mainz Biomed NV's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Mainz Biomed NV's Gross Margin % for the quarter that ended in Dec. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Mainz Biomed NV's Gross Margin % or its related term are showing as below:

MYNZ' s Gross Margin % Range Over the Past 10 Years
Min: -21.71   Med: 32.6   Max: 64.32
Current: 55.92


During the past 6 years, the highest Gross Margin % of Mainz Biomed NV was 64.32%. The lowest was -21.71%. And the median was 32.60%.

MYNZ's Gross Margin % is ranked better than
59.2% of 201 companies
in the Medical Diagnostics & Research industry
Industry Median: 47.88 vs MYNZ: 55.92

Mainz Biomed NV had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Mainz Biomed NV was 0.00% per year.


Mainz Biomed NV Gross Margin % Historical Data

The historical data trend for Mainz Biomed NV's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mainz Biomed NV Gross Margin % Chart

Mainz Biomed NV Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross Margin %
Get a 7-Day Free Trial 24.90 30.85 34.34 56.98 64.32

Mainz Biomed NV Quarterly Data
Dec19 Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Dec24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.84 47.80 62.79 - -

Competitive Comparison of Mainz Biomed NV's Gross Margin %

For the Diagnostics & Research subindustry, Mainz Biomed NV's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mainz Biomed NV's Gross Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Mainz Biomed NV's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Mainz Biomed NV's Gross Margin % falls into.


;
;

Mainz Biomed NV Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Mainz Biomed NV's Gross Margin for the fiscal year that ended in Dec. 2024 is calculated as

Gross Margin % (A: Dec. 2024 )=Gross Profit (A: Dec. 2024 ) / Revenue (A: Dec. 2024 )
=0.6 / 0.894
=(Revenue - Cost of Goods Sold) / Revenue
=(0.894 - 0.319) / 0.894
=64.32 %

Mainz Biomed NV's Gross Margin for the quarter that ended in Dec. 2024 is calculated as


Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Mainz Biomed NV  (NAS:MYNZ) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Mainz Biomed NV had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Mainz Biomed NV Gross Margin % Related Terms

Thank you for viewing the detailed overview of Mainz Biomed NV's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Mainz Biomed NV Business Description

Traded in Other Exchanges
N/A
Address
Robert Koch Strasse 5, Sirius Gutenberg Park, Mainz, RP, DEU, 55129
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.